Previous 10 | Next 10 |
Enlivex Therapeutics (ENLV) and New York City's largest academic medical system Mount Sinai Health System announce a new research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors.Allocetra is a macrophage-reprogramming immun...
-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- Nes Ziona, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Thera...
Nes-Ziona, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced...
Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the underwriter of its previ...
The USPTO has issued a Patent No. 10,927,343 to Enlivex Therapeutics (ENLV) covering Allocetra, the company’s immunotherapy product candidate.The new patent is expected to provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases c...
Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced tha...
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously...
Gainers: Bio-Path Holdings (BPTH) +253%.Cancer Genetics (CGIX) +74%.Torchlight Energy Resources (TRCH) +73%.CM Life Sciences (CMLF) +51%.India Globalization Capital (IGC) +42%.Anchiano Therapeutics (ANCN) +42%.The OLB Group (OLB) +41%.Sundial Growers (SNDL) +40%.Clever Lea...
Comstock Holding Companies (CHCI) -15%.VerifyMe (VRME) -15% on stock offering.Neovasc (NVCN) -14% on stock offering; pared yesterday's gains on patent news.Enlivex Therapeutics (ENLV) -13% on stock offering.Salem Media Group (SALM) -13%.Limbach Holdings (LMB) ...
Enlivex Therapeutics' (ENLV) underwriter has agreed to increase the size of previous offering and purchase ~2.3M ordinary shares at $20.00/share.Expected gross proceeds are ~$46M. Underwriter's over-allotment is an additional ~344.4K shares. Net proceeds will be used for clinical, regulatory,...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...